Botulinum toxins were primary suggested for the neurogenic lower urinary tract dysfunction (LUTD) treatment about thirty years ago. The application of BTX-A in LUTD have just developed and the approval of BTX-A injection confirmed in for patients with both overactive bladders (OAB) and neurogenic detrusor overactivity (NDO). Actually the BTX-A medication in interstitial cystitis/bladder pain syndrome (IC/BPS) is not licensed, but there is under consideration. Despite BTX-A is recommended to treat patients with interstitial cystitis/bladder pain syndrome (ICBPS) under different occasions, its efficacy and safety in the cure of (IC/BPS) is under consideration. One difficulty is related to the toxin delivering systems. It is shown that there is no difference in BTX-A injection to body or trigone but there is a need on further large-scale studies over this subject. Moreover, Hydro distention can boost the therapeutic effect of BTX-A for IC/BPS patients. Additional studies should consider the safety and efficacy of BTX-A injection in the treatment of BTX-A.
American journal of clinical and experimental urology. 2019 Oct 25*** epublish ***
Farbod Torkamand, Seyed Javad Mirjavadi, Fatemeh Khatami, Fateme Guitynavard, Seyed Mohammad Kazem Aghamir
Sina Hospital, Department of Urology, School of Medicine, Tehran University of Medical Sciences Tehran, IRAN., Urology Research Center (URC), Tehran University of Medical Sciences Tehran, IRAN.